THE FUTURE OF KIDNEY CARE IS PROACTIVE. AND IT’S WORKING.
Delorean AI’s Renal AI gives dialysis centers the power to identify patient risk earlier, reduce avoidable hospitalizations, and drive meaningful revenue growth — all while improving patient health outcomes.
IMPROVE PATIENT OUTCOMES. REDUCE HOSPITALIZATIONS. DRIVE ROI.
In just 3 months, 13 clinics using Renal AI saw:
- 34% drop in hospitalizations
- 50% increase in extra treatments (with $155K added revenue)
- 14% fewer no-shows
- 88 hospitalizations avoided — saving ~$758K
Renal Disease
Chronic kidney disease and end-stage
Affects 37 million adults
About 37 million U.S. adults are estimated to have CKD, and most are undiagnosed – IQVIA
40% suffer without diagnosis
40% of people with severely reduced kidney function are not aware of having CKD – IQVIA
According to the CDC, 9 out of 10 adults with CKD do not know they have CKD.
USC Center for Health Policy and Economics states, “patients with ESKD have average monthly spending 33× higher than patients without.
Early Disease burden
Overall health care costs ranged from $26,889 (A1) to $42,139 (A3), and from $28,627 (G2) to $42,902 (G5) per patient per year, demonstrating a considerable early disease burden which continued to increase with declining kidney function. KIREREPORTS Kidney International Reports – February 3, 2023
“Renal AI has transformed our approach to dialysis management, leading to better patient outcomes and cost savings.”
SEE WHY LEADING DIALYSIS PROVIDERS USE RENAL AI
BUILT FOR OPERATIONAL IMPACT
Drive higher-quality care, increase treatments, and reduce costs — without adding staff burden.
REAL-TIME RISK STRATIFICATION
Identify declining health trends before they lead to acute events.
TREATMENT ADHERENCE INSIGHTS
Predict no-shows before they happen and preserve revenue.
PROVEN ROI
For every $1 invested, clinics saved ~$5. Results seen in weeks.